New Device That Detects Cancer Cells Could Help Avoid Invasive Biopsy Surgeries
By LabMedica International staff writers Posted on 28 Feb 2023 |
Cancer is a major contributor to illness and death, and those with suspected cancer may need surgery for a diagnosis, especially for liver, colon or kidney tumors. Unfortunately, biopsies can be uncomfortable, costly, and increase the risk of complications due to surgery. To resolve this problem, researchers have created a new device that can detect and analyze cancer cells from blood samples. This could eliminate the need for a biopsy surgery, as well as allow doctors to monitor treatment progress more accurately.
Researchers from the University of Technology Sydney (UTS, Sydney, Australia) have developed the Static Droplet Microfluidic device, which can quickly detect tumor cells that have migrated away from a primary tumor and into the bloodstream. The device utilizes a distinctive metabolic signature of cancer to separate tumor cells from regular blood cells. After tumor cells are located with the device, they can then be studied genetically and molecularly to support diagnosis and classification of the cancer, allowing for more personalized treatment options.
Circulating tumor cells are a precursor of metastasis, which is responsible for approximately 90% of all cancer-related deaths. Studying these cells may offer greater understanding of the biology behind cancer metastasis, which can help in the development of new treatments. The current liquid biopsy solutions are slow, expensive, and require specialist operators, restricting their use in clinical settings. This new technology is designed to be integrated into research and clinical labs without needing expensive and complex equipment or a trained operator, making it practical and cost-effective for doctors to diagnose and monitor cancer patients.
“Managing cancer through the assessment of tumor cells in blood samples is far less invasive than taking tissue biopsies. It allows doctors to do repeat tests and monitor a patient’s response to treatment,” said Professor Majid Warkiani from the UTS School of Biomedical Engineering.
Related Links:
University of Technology Sydney
Latest Molecular Diagnostics News
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset
- Blood Test Could Detect HPV-Associated Cancers 10 Years before Clinical Diagnosis
- Low-Cost Point-Of-Care Diagnostic to Expand Access to STI Testing
- 18-Gene Urine Test for Prostate Cancer to Help Avoid Unnecessary Biopsies
- Urine-Based Test Detects Head and Neck Cancer
- Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer
- Blood-Based Machine Learning Assay Noninvasively Detects Ovarian Cancer
- Simple PCR Assay Accurately Differentiates Between Small Cell Lung Cancer Subtypes
- Revolutionary T-Cell Analysis Approach Enables Cancer Early Detection
- Single Genetic Test to Accelerate Diagnoses for Rare Developmental Disorders